M&A / Deals Roche and C4 Therapeutics to advance degrader-antibody conjugates research Pharmaceutical TechnologyRoche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer.M&A / DealsOncologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaceutical Technology Roche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer. M&A / DealsOncologyRead full story Post navigation Previous: Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisationNext: Roche places a $1bn bet on C4T degrader-antibody conjugates Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026